Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 4/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973206 | 0.86 | PTGER3 (0.49) | PTGER3PTGER1PTGER4PTGER2ALDH1A1 | |
| SCHEMBL6421622 | 0.85 | PTGER3 (0.57) | PTGER3PTGER1PTGER4PTGER2ALDH1A1 | |
| SCHEMBL3975403 | 0.78 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL731549 | 0.75 | CYP2D6 (0.55) | ALDH1A1CYP2D6CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL4660476 | 0.74 | CYP2C9 (0.54) | PTGER3PTGER1PTGER4PTGER2ALDH1A1 | |
| SCHEMBL3972176 | 0.74 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL3973361 | 0.74 | EGFR (0.52) | KMT2AMEN1EGFRERBB2 | |
| SCHEMBL3977341 | 0.74 | CA1 (0.48) | ALDH1A1EGFRERBB2 | |
| Urea SCHEMBL8693555 | 0.74 | CYP2D6 (0.53) | PTGER3PTGER1PTGER4PTGER2ALDH1A1 | |
| SCHEMBL2691075 | 0.72 | HPGD (0.64) | ALDH1A1CYP2D6CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569602-B2 | Furan derivatives as EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| EP-1673360-B1 | FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-7417068-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-08-26 | — | — | US | disclosed |
| US-20050124676-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124676-A1 | EP4 receptor antagonists | PTGER4, PTGER3, NR4A3 | PTGER3 2/4885PTGER1 4/4885PTGER4 1/4885 |
| US-20080306117-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER3, NR4A3 | PTGER3 2/4885PTGER1 4/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.